Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Subscribe To Our Newsletter & Stay Updated
